Shares of Dr Reddy's Laboratories on Tuesday rose as much as
2 per cent to a day's high of Rs 3,828.35 after the drug firm launched
the generic memantine hydrochloride tablets in the US market.
The drug is used in the treatment of Alzheimer's disease.
Dr Reddy's has launched the tablets in the strengths of 5 mg and 10 mg after getting the approval from the US FDA, it said in a filing to the BSE. The tablets are generic versions of Merz Pharma GmbH & Co KGaA's Namenda tablets.
The Namenda (memantine HCl) tablets brand had US sales of approximately $1.4 billion for the most recent twelve months ending in May 2015, according to IMS Health," Dr Reddy's Laboratories said.
At 9:45 a.m., shares of Dr Reddy's Laboratories were trading 1.4 per cent higher as compared to a 0.20 per cent decline in Sensex
The drug is used in the treatment of Alzheimer's disease.
Dr Reddy's has launched the tablets in the strengths of 5 mg and 10 mg after getting the approval from the US FDA, it said in a filing to the BSE. The tablets are generic versions of Merz Pharma GmbH & Co KGaA's Namenda tablets.
The Namenda (memantine HCl) tablets brand had US sales of approximately $1.4 billion for the most recent twelve months ending in May 2015, according to IMS Health," Dr Reddy's Laboratories said.
At 9:45 a.m., shares of Dr Reddy's Laboratories were trading 1.4 per cent higher as compared to a 0.20 per cent decline in Sensex
No comments:
Post a Comment